Luye Pharma Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Luye Pharma Group şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

Geri Alım Getirisi

Toplam Hissedar Getirisi	0%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	HK$0.123
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 2186 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 2186 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Luye Pharma Group Piyasaya Karşı Temettü Getirisi

2186 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (2186)	0%
Pazarın Alt %25'i (HK)	3.1%
Pazarın En İyi %25'i (HK)	7.9%
Sektör Ortalaması (Pharmaceuticals)	3.7%
Analist tahmini (2186) (3 yıla kadar)	0%

Önemli Temettü: 2186 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 2186 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 2186 Hong Kong piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 2186 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Luye Pharma Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in FY 2022)

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Investor sentiment improves as stock rises 16%

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Full year 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.039 loss in FY 2021)

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan

Luye Pharma Group Ltd. Announces Dulaglutide Injection BA5101 Entered into Phase III Clinical Trial in China

Luye Pharma Group Ltd. Announces Results of A Phase III Clinical Trial of Class 1 New Drug Ly03005 Presented At the 2022 APA Annual Meeting

Luye Pharma Group Ltd. Announces Results of A Phase I Clinical Trial of Lurbinectedin as Second-Line Therapy in Chinese Patients with SCLC Presented At the 2022 Asco Annual Meeting

Luye Pharma Group Ltd., Annual General Meeting, Jun 20, 2022

Luye Pharma Group Ltd. Announces Completion of Phase I Clinical Trial for Class 1 New Drug LY03014 in China

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.039 loss per share (vs CN¥0.22 profit in FY 2020)

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Submits a New Drug Application for Lurbinectedin (LY01017) for Injection

Luye Pharma Group Ltd. Announces New Indications Approved for Boyounuo® (Bevacizumab Injection) in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trials for Monthly Microsphere Injection New Drug LY03009 for Parkinson's Disease in the United States

Luye Pharma Group Ltd. Announces Acceptance of Application for Marketing Authorization in China for Goserelin Acetate Extended-Release Microspheres for Injection (LY01005)

Luye Pharma Group Releases Top-Line Results from A Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for Group\U0027s Innovative Antibody Drug BA1201 in China

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Dulaglutide Injection (BA5101) in China

Luye Pharma Group Ltd.'s New Drug Rivastigmine Multi-Day Transdermal Patch Receives Marketing Authorization from the Medicines & Healthcare Products Regulatory Agency in the United Kingdom

Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia

First half 2021 earnings released: EPS CN¥0.11 (vs CN¥0.17 in 1H 2020)

Luye Pharma Group Ltd. Announces Clinical Trial Application Submitted in the U.S. for the Group's U0027s New Drug LY03015

Shandong Boan Biotechnology Co. Ltd. Submits Investigational New Drug Application for Its New Drug LY-CovMab to the Food and Drug Administration of the U.S

Luye Pharma Group Ltd. Announces Acceptance of Marketing Authorization Application for Class 1 New Drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) in China

Investor sentiment improved over the past week

Luye Pharma Group Ltd. Obtains Approval for Initiating Clinical Trial for its New Drug LY09606 in China

Luye Pharma Group Ltd. Announces Approval for Initiating Clinical Trial for Nivolumab Injection in China

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.44 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.46 in FY 2019)

Luye Pharma Group Ltd. Announces Enrolment of Subjects in Phase I Clinical Trial in the People's Republic of China Commenced in Relation to the Group's Class 1 New Drug LPM3480392 Injection

Luye Pharma Group Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021